Hua Medicine (the Company, HKG: 2552) announced today that the Company has successfully completed a Phase I clinical trial on…
Browsing: Hua Medicine
Hua Medicine (the Company, HKG: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism…
The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li,…
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at…
Hua Medicine (Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type…
Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for…
Hua Medicine (the “Company”, Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder (“MAH”)…
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its…
Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing…
Hua Medicine (the “Company”, Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. HMM0112 is…
Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 Weeks Dorzagliatin-Driven Portfolio Expands Hua Medicine (the “Company”, Stock Code…
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has…